Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

RPG LIFE SCIENCES LTD. - 532983 - Compliance Certificate - Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

 As per the requirement of Regulation 7 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both physical and electronic share transfer facility are maintained during the period April 1, 2022 to March 31, 2023 (both days inclusive) by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which is registered as Registrar & Share Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number : INR000004058.
10-04-2023
Bigul

RPG LIFE SCIENCES LTD. - 532983 - Closure of Trading Window

 This is to inform you that pursuant to the 'Code of Fair Disclosure, Internal Procedures and Conduct for Regulating, Monitoring and Reporting of Trading by Insiders' of the Company and the SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window for dealing in Securities of the Company by Designated Persons and their immediate relatives shall remain closed from Saturday, April 1, 2023 until 48 hours after the declaration of financial results by the Company for the quarter and year ending on March 31, 2023. The date of Board Meeting of the Company for consideration and declaration of the financial results for the quarter and year ending on March 31, 2023 will be intimated in due course. Kindly take this information on record.
31-03-2023
Bigul

RPG LIFE SCIENCES LTD. - 532983 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Please find enclosed herewith intimation of the loss of share certificate as received by us from Link Intime India Private Limited, our Registrar and Share Transfer Agent, being submitted to you pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the same on record.
28-03-2023
Bigul

RPG LIFE SCIENCES LTD. - 532983 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Please find enclosed herewith intimation of issuance of duplicate share certificates as received by us from Link Intime India Private Limited, our Registrar and Transfer Agents, being submitted to you pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the same on record.
17-03-2023
Bigul

RPG LIFE SCIENCES LTD. - 532983 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Please find enclosed herewith intimation of the loss of share certificate as received by us from Link Intime India Private Limited, our Registrar and Share Transfer Agent, being submitted to you pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the same on record.
14-03-2023
Bigul

RPG LIFE SCIENCES LTD. - 532983 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate

 Please find enclosed herewith intimation of issuance of duplicate share certificates as received by us from Link Intime India Private Limited, our Registrar and Transfer Agents, being submitted to you pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Kindly take the same on record.
16-02-2023
Bigul

RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 Pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, please find below the details of Analyst/Institutional Investors meet which will be participated by the Company along with the presentation to be made at the same. Kindly take the above on record.
03-02-2023
Bigul

RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Newspaper Publication

 In terms of the Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the newspaper publications with respect to Unaudited Financial Results for the quarter and nine months ended December 31, 2022. Kindly take this information on record.
02-02-2023
Bigul

RPG LIFE SCIENCES LTD. - 532983 - Announcement under Regulation 30 (LODR)-Investor Presentation

 Please find enclosed herewith a copy of Investor Presentation with respect to Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022. Kindly take the same on record.
02-02-2023
Bigul

Q3FY23 Quarterly Result Announced for RPG Life Sciences Ltd.

 Pharmaceuticals firm RPG Life Sciences announced Q3FY23 results: Q3FY23 & 9MFY23: RPG Life Sciences posted a jump in PBT by 25% YoY for Q3FY23, maintaining the upward trajectory in EBITDA margins, which improved from 21.4% to 22.8% YoY. Revenue from operations at Rs 130.60 crores registered a growth of 13% YoY for Q3FY23. For 9MFY23 too, the company posted a jump in PBT by 25% YoY and recorded EBITDA margin expansion from 22.2% to 22.8% YoY. Revenue from operations at Rs 394.32 crores registered a growth of 17% YoY for 9MFY23. Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, “In Q3 FY23, Company maintained its upward trajectory of overall robust performance by posting yet another strong results despite the ongoing geo-political challenges impacting supply chain and costs. Revenue and PBT grew by healthy 13% and 25% respectively YoY. EBITDA margin grew from 21.4% to 22.8% YoY. Domestic Formulations business, the biggest contributor to company business, recorded robust growth both in value and volumes - significantly and consistently ahead of the market. While our comprehensive life cycle management program for legacy brands is helping them register healthy growth, our new product portfolio comprising of newer and progressive segments is also witnessing an impressive uptake. Our foray into Rheumatology has strengthened our Specialty segment. Our MABs portfolio is continuing to post robust performance. Our digitalization initiatives are showing strong traction. Salesforce productivity continues to register healthy upward momentum across business segments. International Formulations business has also shown robust growth while API business has also picked up growth momentum. Our relentless focus on achieving cost efficiencies in our operations, eye on sales hygiene, is helping us to consistently improve our margins. We are well on course to implement our Transformation Agenda to achieve our strategic goals.” Result PDF
01-02-2023
Next Page
Close

Let's Open Free Demat Account